European Parliament ECR amendment seeks to pause UWWTD pharmaceutical cost obligations pending supply security study

A single amendment to a European Parliament resolution on the Urban Wastewater Treatment Directive (UWWTD), proposed by the European Conservatives and Reformists (ECR) group, would suspend key financial and technical obligations for the pharmaceutical sector until the European Commission completes a study on the directive's impact on medicine supply security. The amendment, submitted to the plenary resolution B-10-2026-0282, targets the Extended Producer Responsibility (EPR) scheme and quaternary treatment requirements for micropollutants, arguing that these provisions risk exacerbating medicine shortages and undermining Europe's strategic autonomy in healthcare.

The amendment expands the scope of a proposed suspension beyond the original text's focus on EPR provisions (Articles 9 and 10) to also include quaternary treatment obligations. Quaternary treatment involves advanced processes such as ozonation or activated carbon to remove pharmaceutical residues from wastewater. By including this, the amendment would pause both the financial burden on producers (via EPR fees) and the technical compliance burden on wastewater operators, effectively creating a regulatory standstill on the directive's most impactful provisions until the Commission's study is completed and assessed.

Political landscape

Only the ECR group submitted an amendment, making their position the sole challenge to the original text. The ECR argues that the UWWTD's environmental goals must be balanced against the risk of disrupting medicine production, advocating a conditional suspension pending a risk assessment. Other political groups—including the EPP, S&D, Renew, Greens/EFA, The Left, and ID—did not propose amendments, implying broad support for the original motion's timeline for implementing EPR and quaternary treatment. These groups likely view the environmental and public health benefits of reducing pharmaceutical residues in water as paramount and not sufficiently threatened by supply chain risks.

Impact on stakeholders

The amendment, if adopted, would have moderate to major impacts on several stakeholders:

- Pharmaceutical industry: Positive impact in the short term, as it would delay costly EPR fees and quaternary treatment investments, potentially preserving production margins and reducing the risk of shortages. Negative impact in the long term if the study leads to permanent exemptions, as the industry would face continued pressure to address environmental concerns. - Wastewater operators: Positive impact from delayed quaternary treatment installation costs, but negative impact from continued uncertainty about future technical requirements and financing. - EU environmental regulators and water quality authorities: Negative impact, as the suspension would delay the reduction of pharmaceutical micropollutants in water bodies, potentially undermining the directive's public health and environmental objectives. - EU consumers and patients: Mixed impact. Positive if the suspension prevents medicine shortages and ensures supply security. Negative if delayed treatment leads to higher pharmaceutical residues in drinking water, with potential long-term health risks.

Institutional follow-up

The amendment will be debated and voted on during the European Parliament plenary session. If adopted, it would modify the resolution's call on the Commission. The resolution itself is non-binding, but it signals parliamentary pressure. The Commission would then decide whether to initiate the requested study and consider a temporary suspension of the directive's provisions. The Council's position on the UWWTD implementation remains to be seen, and any legislative changes would require a formal revision of the directive through the ordinary legislative procedure.